Success in This New Battleground Could Make Eli Lilly and Novo Nordisk Stock Absolutely Fly for Years

These two players are set on finding the next big therapeutic modality.Eli Lilly (LLY -3.47%) and Novo Nordisk (NVO -2.85%) are archrivals thanks to their dueling drugs for weight loss, Zepbound and Wegovy, as well as their competing therapies for type 2 diabetes, Mounjaro and Ozempic.But dominance in a pharmaceutical segment never lasts forever. Over a long-enough period, new entrants can copy the winners' products and produce generic versions for a fraction of the cost. Therefore, ongoing innovation is th ...